No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
TTY Biopharm Company Limited, along with its associated entities, specializes in the creation and distribution of pharmaceutical and chemical products across Taiwan and global markets. Its operations are structured into several key divisions: Oncology, Intensive Care, Healthcare, Export & CDMO, and an "Other" Business Unit. For anti-cancer and supportive therapies, the company markets a range of oncology medications under prominent brand names such as Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre. Addressing infectious diseases and influenza, TTY Biopharm supplies anti-infection drugs including Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax. Furthermore, the firm offers various healthcare-related pharmaceuticals designed for the digestive system, osteoporosis, and metabolic conditions, marketed under brands like Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin. Beyond pharmaceuticals, the company is also involved in distributing functional foods, conducting international trade (import/export), and engaging in investment ventures. Established in 1960, TTY Biopharm maintains its principal office in Taipei, Taiwan.
www.tty.com.twNo one on the platform currently holds 4105.TWO.
No tracked institution reports a position in 4105.TWO as of their last filing.
No one on the platform has traded 4105.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 22.0% | 19.4% | — | — | — | |
| Rev. Growth % | 9.5% | 8.9% | ||||
| Profit Margin % | 24.2% | 21.8% | ||||
| Free Cash Flow Margin % | 25.0% | 22.3% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $7.0B | +8.4% | $7.27 | $7.27–$7.27 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $1.59 | $1.63 | +2.5% |
| 2026-05-06 | $1.36 | $1.78 | +30.9% |
| 2026-03-09 | $1.72 | $1.22 | -29.1% |
| 2025-11-11 | $1.41 | $2.33 | +65.2% |
| 2025-08-05 | $1.08 | $1.14 | +5.6% |
| 2025-05-14 | $1.08 | $1.57 | +45.4% |
| 2025-02-26 | $1.23 | $2.15 | +74.8% |
| 2024-11-14 | $1.32 | $1.50 | +13.6% |
| $56.00 |
| +0.00% |
| $14.9B |
| — |
| 4114.TWOSynmosa Biopharma Corporation | $29.35 | +0.00% | $15.8B | — |
| 4147.TWOTaiMed Biologics Inc. | $60.80 | +2.01% | $16.5B | — |
Source: Financial Modeling Prep · peers by sector/industry